Inflammatory bowel disease: Established and evolving considerations on its etiopathogenesis and therapy

被引:120
作者
Schirbel, Anja [2 ]
Fiocchi, Claudio [1 ]
机构
[1] Cleveland Clin Fdn, Dept Gastroenterol & Hepatol, Dept Pathobiol, Lerner Res Inst, Cleveland, OH 44195 USA
[2] Charite, Campus Virchow Klinikum, Dept Gastroenterol & Hepatol, D-13353 Berlin, Germany
关键词
Crohn's disease; genetics; intestinal microbiota; inflammatory bowel disease; pathogenesis; ulcerative colitis; INTESTINAL MONONUCLEAR-CELLS; GENOME-WIDE ASSOCIATION; INVASIVE ESCHERICHIA-COLI; REGULATORY T-CELLS; CROHNS-DISEASE; ULCERATIVE-COLITIS; LAMINA PROPRIA; INCREASED EXPRESSION; PERIPHERAL-BLOOD; IMMUNE-RESPONSES;
D O I
10.1111/j.1751-2980.2010.00449.x
中图分类号
R57 [消化系及腹部疾病];
学科分类号
100201 [内科学];
摘要
Modern studies of inflammatory bowel disease (IBD) pathogenesis have been pursued for about four decades, a period of time where the pace of progress has been steadily increasing. This progress has occurred in parallel with and is largely due to developments in multiple basic scientific disciplines that range from population and social studies, genetics, microbiology, immunology, biochemistry, cellular and molecular biology, and DNA engineering. From this cumulative and constantly expanding knowledge base the fundamental pillars of IBD pathogenesis appear to have been identified and consolidated during the last couple of decades. Presently there is a general consensus among basic IBD investigators that both Crohn's disease (CD) and ulcerative colitis (UC) are the result of the combined effects of four basic components: global changes in the environment, the input of multiple genetic variations, alterations in the intestinal microbiota, and aberrations of innate and adaptive immune responses. There is also agreement on the conclusion that none of these four components can by itself trigger or maintain intestinal inflammation. A combination of various factors, and most likely of all four factors, is probably needed to bring about CD or UC in individual patients, but each patient or set of patients seems to have a different combination of alterations leading to the disease. This would imply that different causes and diverse mechanisms underlie IBD, and this could also explain why every patient displays his or her own clinical manifestations and a personalized response to therapy, and requires tailored approaches with different medications. While we are becoming increasingly aware of the importance of this individual variability, we have only a superficial notion of the reasons why this occurs, as hinted by the uniqueness of the genetic background and of the gut flora in each person. So, we are apparently facing the paradox of having to deal with the tremendous complexity of the mechanisms responsible for chronic intestinal inflammation in the setting of each patient's individuality in the response to this biological complexity. This obviously poses considerable challenges to reaching a full understanding of IBD pathogenesis, but being aware of the difficulties is the first step in finding answers to them.
引用
收藏
页码:266 / 276
页数:11
相关论文
共 114 条
[1]
Inflammatory bowel disease in the Asia-Pacific area: A comparison with developed countries and regional differences [J].
Ahuja, Vineet ;
Tandon, Rakesh K. .
JOURNAL OF DIGESTIVE DISEASES, 2010, 11 (03) :134-147
[2]
Phenotypic and functional features of human Th17 cells [J].
Annunziato, Francesco ;
Cosmi, Lorenzo ;
Santarlasci, Veronica ;
Maggi, Laura ;
Liotta, Francesco ;
Mazzinghi, Benedetta ;
Parente, Eliana ;
Fili, Lucia ;
Ferri, Simona ;
Frosali, Francesca ;
Giudici, Francesco ;
Romagnani, Paola ;
Parronchi, Paola ;
Tonelli, Francesco ;
Maggi, Enrico ;
Romagnani, Sergio .
JOURNAL OF EXPERIMENTAL MEDICINE, 2007, 204 (08) :1849-1861
[3]
Heterogeneity of human effector CD4+ T cells [J].
Annunziato, Francesco ;
Romagnani, Sergio .
ARTHRITIS RESEARCH & THERAPY, 2009, 11 (06)
[4]
Do studies in humans better depict Th17 cells? [J].
Annunziato, Francesco ;
Romagnani, Sergio .
BLOOD, 2009, 114 (11) :2213-2219
[5]
Embrace the complexity [J].
不详 .
NATURE IMMUNOLOGY, 2009, 10 (04) :325-325
[6]
Arend P, 1970, Am J Proctol, V21, P331
[7]
Mucosal gene signatures to predict response to infliximab in patients with ulcerative colitis [J].
Arijs, I. ;
Li, K. ;
Toedter, G. ;
Quintens, R. ;
Van Lommel, L. ;
Van Steen, K. ;
Leemans, P. ;
De Hertogh, G. ;
Lemaire, K. ;
Ferrante, M. ;
Schnitzler, F. ;
Thorrez, L. ;
Ma, K. ;
Song, X. -Y R. ;
Marano, C. ;
Van Assche, G. ;
Vermeire, S. ;
Geboes, K. ;
Schuit, F. ;
Baribaud, F. ;
Rutgeerts, P. .
GUT, 2009, 58 (12) :1612-1619
[8]
Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease [J].
Barrett, Jeffrey C. ;
Hansoul, Sarah ;
Nicolae, Dan L. ;
Cho, Judy H. ;
Duerr, Richard H. ;
Rioux, John D. ;
Brant, Steven R. ;
Silverberg, Mark S. ;
Taylor, Kent D. ;
Barmada, M. Michael ;
Bitton, Alain ;
Dassopoulos, Themistocles ;
Datta, Lisa Wu ;
Green, Todd ;
Griffiths, Anne M. ;
Kistner, Emily O. ;
Murtha, Michael T. ;
Regueiro, Miguel D. ;
Rotter, Jerome I. ;
Schumm, L. Philip ;
Steinhart, A. Hillary ;
Targan, Stephan R. ;
Xavier, Ramnik J. ;
Libioulle, Cecile ;
Sandor, Cynthia ;
Lathrop, Mark ;
Belaiche, Jacques ;
Dewit, Olivier ;
Gut, Ivo ;
Heath, Simon ;
Laukens, Debby ;
Mni, Myriam ;
Rutgeerts, Paul ;
Van Gossum, Andre ;
Zelenika, Diana ;
Franchimont, Denis ;
Hugot, Jean-Pierre ;
de Vos, Martine ;
Vermeire, Severine ;
Louis, Edouard ;
Cardon, Lon R. ;
Anderson, Carl A. ;
Drummond, Hazel ;
Nimmo, Elaine ;
Ahmad, Tariq ;
Prescott, Natalie J. ;
Onnie, Clive M. ;
Fisher, Sheila A. ;
Marchini, Jonathan ;
Ghori, Jilur .
NATURE GENETICS, 2008, 40 (08) :955-962
[9]
Gastroenterology 2 - Inflammatory bowel disease: clinical aspects and established and evolving therapies [J].
Baumgart, Daniel C. ;
Sandborn, William J. .
LANCET, 2007, 369 (9573) :1641-1657
[10]
Biomarkers in inflammatory bowel disease [J].
Beaven, SW ;
Abreu, MT .
CURRENT OPINION IN GASTROENTEROLOGY, 2004, 20 (04) :318-327